Life Science REIT Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-13.98	-21.71	-27.61	18.58
Asset Writedown	17.38	22.85	31.31	-19.29
Change in Accounts Receivable	3.91	-5.18	-8.14	-7.61
Change in Other Net Operating Assets	-0.58	4.22	2.68	17.02
Other Operating Activities	6.19	7.43	0.67	-0.21
Operating Cash Flow	12.92	7.62	-1.09	8.49
Operating Cash Flow Growth	69.68%	-	-	-
Acquisition of Real Estate Assets	-20.41	-24.03	-187.06	-435.66
Sale of Real Estate Assets	-	9.17	-	-
Net Sale / Acq. of Real Estate Assets	-20.41	-14.87	-187.06	-435.66
Other Investing Activities	4.06	3.22	0.68	0.02
Investing Cash Flow	-16.35	-11.64	-186.38	-435.64
Long-Term Debt Issued	14	142.52	101.26	-
Long-Term Debt Repaid	-	-145.3	-26.26	-
Net Debt Issued (Repaid)	14	-2.78	75	-
Issuance of Common Stock	-	-	-	840
Common Dividends Paid	-7	-14	-3.5	-
Other Financing Activities	-12.35	-10.45	-4.39	-14.54
Net Cash Flow	-8.77	-31.27	-120.36	398.31
Cash Interest Paid	12.35	9.47	2.07	-
Levered Free Cash Flow	-19.4	-23.92	-7.19	-
Unlevered Free Cash Flow	-12.91	-17.92	-4.83	-
Change in Net Working Capital	-0.38	-0.75	0.52	-

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.